ADVERTISEMENT

PBMs

Trump II, Year One: Updated Version Seems Buggy For Pharma

Issues that had been concerns in Trump’s first term are realities now, but industry has also seen some successes. Trump’s personalistic style of governance means that larger firms may be at an advantage because of their greater flexibility to cut deals on individual products.

Arizonans To Be Offered Up To 80% Discount On Generic Drugs

Arizona’s governor Katie Hobbs pointed to Trump’s One Big Beautiful Bill and other federal failures as she signed an executive order to increase access to medications in her state.

PBMs Tighten The Reins: Value Becomes The New Access Gatekeeper

Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.

Is Optum Rx Payment Remodel To Favor Generics A Peace Offering For US FTC?

Optum Rx, one of the largest PBMs in the US, declared it was the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.

Optum Rx Remodels Payment Model To Favor Generics – A Peace Offering For FTC?

Optum Rx, one of the largest PBMs in the US, declared itself as the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.

Incoming US FTC Chair Endorses Agency Report Challenging PBM Generic Drug Markups

Chairman-designee Andrew Ferguson likely will continue the commission’s investigation of PBMs during the next administration.

Looming Step Therapy Ban In Illinois Is ‘Game Changer,’ Could Start Trend

Federal legislation on PBM reforms has stalled, but state efforts remain active. Illinois’ Healthcare Protection Act includes several other limits on insurer power, including prohibiting prior authorization for inpatient mental health care.

Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes

Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.

With Reform Efforts Persisting, PBM Trade Association Sets Lobbying Record

Infographic details who gave what to whom as all segments of the US healthcare industry gear up for the presidential election cycle.

Mark Cuban: Pharma’s Secret Weapon In The Fight Against PBMs

The well-known businessman and TV personality told the White House that the US needs to ‘stop doing business with the big three PBMs,’ helping to fight the drug industry’s battle against the middlemen with a friendlier face not associated directly with the brand industry.

PBM Action Lags In Congress And At FTC As Targeting Commercial Plans Divides Republicans

PBM reform isn’t expected to ride along with the next government funding packages, which could push any prospect of legislative reform closer to 2025. Meanwhile FTC says it is facing difficulty getting all the information for its investigation. 

Birth Control Guidance For Insurers Aims To Boost Coverage, Smooth Exemption ‘Pathway’

Three-agency guidance, issued as Biden administration is hoping to emphasize reproductive rights in its reelection campaign, outlines the narrow set of circumstances in which a health plan doesn’t have to fully cover certain types of birth control.